BZDS1901 manufacturing agreement
Filed with ASX · · 6 pages · English
Earlier from AdAlta
- Automated cell therapy manufacturing MoU
- BZDS1901 clinical update
- AdCella and SHcell hold first JDC meeting
- New AD-214 patent granted
- AdCella expands clinical advisory board
Later from AdAlta
- $2.5m placement
- Regulatory advisors appointed for BZDS1901
- Second BZDS1901 milestone paid
- Oktopi AI collaboration for research efficiency
- 2 year survival milestone for EW-001 patient
Follow AdAlta into a list and get an email when it puts out news.
Follow AdAlta